Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Agnosia 1

Interventions

Bevacizumab 19 Paclitaxel 16 Carboplatin 12 pembrolizumab 11 liposomal doxorubicin 10 Cyclophosphamide 9 Specimen Handling 8 Gemcitabine 8 olaparib 7 fludarabine 7 Topotecan 7 Magnetic Resonance Spectroscopy 7 Taxes 5 Immunoglobulin G 5 Fulvestrant 5 Disulfides 5 niraparib 4 Oxaliplatin 4 Nivolumab 4 Biopsy 4 trastuzumab deruxtecan 3 palbociclib 3 mirvetuximab soravtansine 3 aldesleukin 3 Leucovorin 3 Fluorouracil 3 1-dodecylpyridoxal 3 ulixertinib 2 nilotinib 2 ipatasertib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Acetaminophen × 30 days × Clear all

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡